CRISPR/Cas9-engineering of Kell null erythrocytes to unveil host targeted irresistible antimalarial. - Kumari G; Gupta P; Goswami SG; Jain R; Anand S; Biswas S; Garg S; Thakur P; Saravanakumar V; Arvinden VR; Goswami B; Bhowmick IP; et al. (Communications biology, 2025)